Dose adjustment in renal impairment
Dose adjustment may be needed in kidney disease.
Leaflet QUIXIDAR 5mg / 0.4ml solution for injection in pre-filled syringe
- Product code:
- W51702001
- Quantity:
- 2
- Indicated for:
- prevention and treatment of thromboembolism
- Route of administration:
- injectable
- Substance:
- fondaparinux sodium (anticoagulant)
- ATC
- B01AX05 — Blood and blood forming organs | Antithrombotic agents | Antithrombotic agents | Other antithrombotic agents
Precautions:
Major drug interactions
This medicine may have important interactions with other medicines.
Additional monitoring
This medicine is subject to additional monitoring.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Bleeding risk
This medicine may increase the risk of bleeding.
Fondaparinux sodium is an anticoagulant medication used to prevent and treat blood clots, such as deep vein thrombosis or pulmonary embolism. It works by inhibiting a key factor involved in blood coagulation, thereby reducing the risk of dangerous clot formation.
It is administered by subcutaneous injection, usually once daily, as directed by the doctor. The dose is determined based on body weight and the patient's individual risk. It is important to follow the treatment regularly and not to stop it without medical advice.
Side effects may include bleeding, bruising at the injection site, anemia, or, more rarely, allergic reactions. In very rare cases, serious complications such as a decrease in platelet count or severe hypersensitivity reactions may occur.
Fondaparinux sodium is an effective and safe option for preventing thrombotic complications, but it requires careful monitoring and strict adherence to medical recommendations to minimize the risks associated with treatment.
It is administered by subcutaneous injection, usually once daily, as directed by the doctor. The dose is determined based on body weight and the patient's individual risk. It is important to follow the treatment regularly and not to stop it without medical advice.
Side effects may include bleeding, bruising at the injection site, anemia, or, more rarely, allergic reactions. In very rare cases, serious complications such as a decrease in platelet count or severe hypersensitivity reactions may occur.
Fondaparinux sodium is an effective and safe option for preventing thrombotic complications, but it requires careful monitoring and strict adherence to medical recommendations to minimize the risks associated with treatment.
General data about QUIXIDAR 5mg / 0.4ml
- Substance:
- fondaparinux sodium
- Date of latest medicines list:
- 01-07-2013
- Product code:
- W51702001
- Concentration:
- 5mg / 0.4ml
- Pharmaceutical form:
- solution for injection in pre-filled syringe
- Quantity:
- 2
- Product type:
- Original
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for fondaparinux sodium
Concentrations available for fondaparinux sodium
- 1.5mg/0.3ml
- 10mg/0.8ml
- 2.5mg/0.5ml
- 5mg/0.4ml
- 7.5mg/0.6ml